Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1991-6-11
|
pubmed:abstractText |
Sixty-five patients (20 patients who had had prior radiotherapy and 45 patients who had not had prior radiotherapy) were entered into a study evaluating escalating doses of etoposide and mitomycin in the treatment of non-small-cell lung cancer (NSCLC). Twenty-two percent of patients who had not received prior radiotherapy responded to the chemotherapy, compared with 5% of patients who had received prior radiotherapy. The best response rate and median survival time was 30% and 31.9 weeks, respectively, seen in three of 10 patients receiving mitomycin 10 mg/M2 i.v. day 1 and etoposide 100 mg/M2 i.v. days 1-3. The major toxicity was hematologic--mainly leukopenia, in 59% of patients who had had no prior radiation therapy and were receiving mitomycin 10 mg/M2 i.v. day 1 and etoposide 150 mg/M2 i.v. days 1-3 (grade 3 and 4 hematologic toxicity). The mitomycin-etoposide drug combination has some activity in patients with NSCLC who have not received prior radiotherapy. The recommended starting dose is mitomycin 10 mg/M2 i.v. day 1 and etoposide 100 mg/M2 i.v. days 1-3, administered every 4 weeks.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0277-3732
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
127-32
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1851388-Adenocarcinoma,
pubmed-meshheading:1851388-Adult,
pubmed-meshheading:1851388-Aged,
pubmed-meshheading:1851388-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1851388-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:1851388-Carcinoma, Squamous Cell,
pubmed-meshheading:1851388-Drug Evaluation,
pubmed-meshheading:1851388-Etoposide,
pubmed-meshheading:1851388-Female,
pubmed-meshheading:1851388-Humans,
pubmed-meshheading:1851388-Leukopenia,
pubmed-meshheading:1851388-Lung Neoplasms,
pubmed-meshheading:1851388-Male,
pubmed-meshheading:1851388-Middle Aged,
pubmed-meshheading:1851388-Mitomycins,
pubmed-meshheading:1851388-Remission Induction,
pubmed-meshheading:1851388-Survival Rate,
pubmed-meshheading:1851388-Time Factors
|
pubmed:year |
1991
|
pubmed:articleTitle |
Etoposide and mitomycin in the treatment of non-small-cell lung cancer. A phase I-II evaluation.
|
pubmed:affiliation |
Johns Hopkins Oncology Center, Baltimore, MD 21205.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|